- Home
- ENVB vs SGBX Comparison
ENVB vs SGBX Comparison
Compare ENVB & SGBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENVB
- SGBX
- Stock Information
- Founded
- ENVB 1994
- SGBX 2007
- Country
- ENVB United States
- SGBX United States
- Employees
- ENVB N/A
- SGBX N/A
- Industry
- ENVB Biotechnology: Pharmaceutical Preparations
- SGBX RETAIL: Building Materials
- Sector
- ENVB Health Care
- SGBX Consumer Discretionary
- Exchange
- ENVB Nasdaq
- SGBX Nasdaq
- Market Cap
- ENVB 3.1M
- SGBX 2.7M
- IPO Year
- ENVB N/A
- SGBX 2017
- Fundamental
- Price
- ENVB $1.32
- SGBX $0.64
- Analyst Decision
- ENVB Strong Buy
- SGBX
- Analyst Count
- ENVB 1
- SGBX 0
- Target Price
- ENVB $10.00
- SGBX N/A
- AVG Volume (30 Days)
- ENVB 107.1K
- SGBX 1.0M
- Earning Date
- ENVB 08-11-2025
- SGBX 08-13-2025
- Dividend Yield
- ENVB N/A
- SGBX N/A
- EPS Growth
- ENVB N/A
- SGBX N/A
- EPS
- ENVB N/A
- SGBX N/A
- Revenue
- ENVB N/A
- SGBX $4,574,857.00
- Revenue This Year
- ENVB N/A
- SGBX $1,628.82
- Revenue Next Year
- ENVB N/A
- SGBX N/A
- P/E Ratio
- ENVB N/A
- SGBX N/A
- Revenue Growth
- ENVB N/A
- SGBX N/A
- 52 Week Low
- ENVB $1.01
- SGBX $0.30
- 52 Week High
- ENVB $11.55
- SGBX $2.64
- Technical
- Relative Strength Index (RSI)
- ENVB 57.52
- SGBX 45.76
- Support Level
- ENVB $1.19
- SGBX $0.60
- Resistance Level
- ENVB $1.28
- SGBX $0.68
- Average True Range (ATR)
- ENVB 0.06
- SGBX 0.06
- MACD
- ENVB 0.02
- SGBX -0.01
- Stochastic Oscillator
- ENVB 91.48
- SGBX 18.23
About ENVB Enveric Biosciences Inc.
Enveric Biosciences Inc is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of depression, anxiety, addiction, and other psychiatric disorders. The company's program, EB-003, is a first-in-class approach to the treatment of difficult-to-address mental health disorders designed to promote neuroplasticity without inducing hallucinations in the patient. The company is also developing EB-002, formerly EB-373, a next-generation synthetic prodrug of the active metabolite, psilocin, which is being studied as a treatment for psychiatric disorders.
About SGBX Safe & Green Holdings Corp.
Safe & Green Holdings Corp is a modular solutions company. The company currently provides modules made out of both code-engineered cargo shipping containers and wood for use as both permanent or temporary structures for residential housing use and commercial use, including for health care facilities. It operates in four segments: construction services; medical; real estate development; and environmental. The company generates the majority of its revenue from the Construction segment includes the company's manufacturing unit SG ECHO and other modules projects.